India may now be taking compulsory licensing one step further, with domestic Natco Pharma asking the country's patent office to deny Gilead Sciences protection on its brand-new hep C treatment in the first place.
written on 11.04.2014
India may now be taking compulsory licensing one step further, with domestic Natco Pharma asking the country's patent office to deny Gilead Sciences protection on its brand-new hep C treatment in the first place.
See our Cookie Privacy Policy Here